AT-533,908112-37-8

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

AT-533

CAS No. : 908112-37-8

MCE 国际站：AT-533

产品活性：AT-533 是一种有效的 Hsp90 和 HSV 抑制剂。AT-533 通过阻断 HIF-1α/VEGF/VEGFR-2 信号通路抑制肿瘤生长和血管生成。AT-533 还抑制下游通路的激活，包括 Akt/mTOR/p70S6K, Erk1/2 和 FAK。AT-533 抑制人脐静脉内皮细胞 (HUVEC) 的管形成、细胞迁移和侵袭。

研究领域：Cell Cycle/DNA Damage  |  Metabolic Enzyme/Protease  |  Anti-infection  |  Protein Tyrosine Kinase/RTK  |  NF-κB  |  MAPK/ERK Pathway  |  Stem Cell/Wnt  |  PI3K/Akt/mTOR

作用靶点：HSP  |  HSV  |  HIF/HIF Prolyl-Hydroxylase  |  VEGFR  |  NF-κB  |  ERK  |  Akt  |  FAK

In Vitro: AT-533 (0-1350 nM; 24 h or 48 h) inhibits 20 ng/mL VEGF-induced tube formation, cell migration, and invasion of HUVECs.
AT-533 (2 μM or 75 μM; 24 h) inhibits the HIF-1α/VEGF signaling pathway in hypoxia-induced breast cancer cells, as well as inhibiting Akt/mTOR/p70S6K, Erk1/2, and FAK phosphorylation.
AT-533 (10 nM, 50 nM; 48 h) shows anti-angiogenic ability in chorioallantoic membrane (CAM) model.
AT-533 (0.5 μM; 2 h, 4 h) decreases TNF-α, IL-1β and IL-6 production in RAW264.7 and BV2 cells induced by HSV-1.

In Vivo: AT-533 (10 mg/kg; i.p.; once daily for 21 d) suppresses the expression of the HIF-1α/VEGF signaling pathway-related proteins in MDA-MB-231 breast cancer xenografts tumor model in mouse.
AT-533 (1, 2 and 4 mg/kg; i.p.; once daily for 30 d) has no mortality, loss of appetite and body weight, adverse reactions in Sprague-Dawley rats in subacute toxicity test.

相关产品：Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Metabolism/Protease Compound Library  |  NF-κB Signaling Compound Library  |  PI3K/Akt/mTOR Compound Library  |  Protein Tyrosine Kinase Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Antioxidant Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Endoplasmic Reticulum Stress Compound Library  |  Glycolysis Compound Library  |  Pyroptosis Compound Library  |  Cytoskeleton Compound Library  |  Glutamine Metabolism Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Transcription Factor-Targeted Library  |  Glucose Metabolism Compound Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Antidepressant Compound Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Cancer Stem Cells Compound Library  |  Pain-Related Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Cytokine Inhibitors Library  |  Serine/Threonine Kinase Inhibitor Library  |  Phorbol 12-myristate 13-acetate  |  Tamoxifen  |  2-Deoxy-D-glucose  |  Deferoxamine mesylate  |  Bortezomib  |  Sorafenib  |  MK-2206 dihydrochloride  |  Brefeldin A  |  PD98059  |  BAY 11-7082  |  Lenvatinib  |  SC79  |  Cytarabine  |  Palmitic acid  |  Yoda 1  |  Polyinosinic-polycytidylic acid  |  DMOG  |  Sunitinib  |  TAK-243  |  Regorafenib  |  Afatinib  |  Capivasertib  |  Nintedanib  |  PX-478  |  Bevacizumab  |  Semaxinib  |  SCH772984  |  TBHQ  |  Cabozantinib  |  JSH-23

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds